Literature DB >> 12468814

Clinical and serological associations of ribosomal P autoantibodies in systemic lupus erythematosus: prospective evaluation in a large cohort of Italian patients.

R Gerli1, L Caponi, A Tincani, R Scorza, M G Sabbadini, M G Danieli, V De Angelis, M Cesarotti, M Piccirilli, R Quartesan, P Moretti, C Cantoni, F Franceschini, I Cavazzana, L Origgi, M Vanoli, E Bozzolo, L Ferrario, A Padovani, O Gambini, L Vanzulli, D Croce, S Bombardieri.   

Abstract

OBJECTIVE: To verify the association of ribosomal anti-P antibodies (anti-P), as detected by a sensitive ELISA, with serological findings and clinical manifestations, including neuropsychiatric involvement evaluated according to the American College of Rheumatology (ACR) nomenclature, in a large cohort of patients with systemic lupus erythematosus (SLE).
METHODS: Anti-P were evaluated in the serum of 149 consecutive Italian SLE patients by an ELISA using a multiple antigen peptide carrying four copies of a common P0, P1 and P2 epitope. A complete laboratory evaluation and clinical examination were performed in each patient. In addition, all patients underwent an accurate neuropsychiatric and neuropsychological assessment performed by trained specialists according to the 1999 ACR suggestions.
RESULTS: Serum anti-P were detected in 18/149 patients (12.1%). The anti-P prevalence was similar (11.7%) when the analysis was performed in a larger series of sera including 82 additional SLE patients, who were not included in the clinical study. The age of anti-P-positive patients at disease onset was less than 33 yr and, in comparison with the anti-P-negative patients, these patients showed more active disease activity and a higher prevalence of photosensitivity and malar and discoid rash. A strong association between IgG anticardiolipin antibodies and anti-P was also found. However, anti-P were associated with neither neuropsychiatric syndromes nor cognitive impairment.
CONCLUSION: This study does not seem to confirm the described association of anti-P with SLE neuropsychiatric manifestations. However, it supports the anti-P association with different skin manifestations as well as the presence of anticardiolipin in a subset of patients with SLE characterized by early disease onset.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12468814     DOI: 10.1093/rheumatology/41.12.1357

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  22 in total

Review 1.  Autoantibodies involved in neuropsychiatric manifestations associated with systemic lupus erythematosus: a systematic review.

Authors:  Savino Sciascia; Maria Laura Bertolaccini; Dario Roccatello; Munther A Khamashta; Giovanni Sanna
Journal:  J Neurol       Date:  2014-06-21       Impact factor: 4.849

2.  Cutaneous vasculitis in systemic lupus erythematosus: association with anti-ribosomal P protein antibody and Raynaud phenomenon.

Authors:  Samuel Katsuyuki Shinjo; Eloísa Bonfá
Journal:  Clin Rheumatol       Date:  2010-03-28       Impact factor: 2.980

Review 3.  Anti-ribosomal-P antibodies in lupus nephritis, neuropsychiatric lupus, lupus hepatitis, and Chagas' disease: promising yet limited in clinical utility.

Authors:  Mary Abraham; Chris T Derk
Journal:  Rheumatol Int       Date:  2014-06-07       Impact factor: 2.631

4.  Major immunoreactive domains of human ribosomal P proteins lie N-terminal to a homologous C-22 sequence: application to a novel ELISA for systemic lupus erythematosus.

Authors:  J L J Lin; V Dubljevic; M J Fritzler; Ban-Hock Toh
Journal:  Clin Exp Immunol       Date:  2005-07       Impact factor: 4.330

5.  Ribosomal P autoantibodies are present before SLE onset and are directed against non-C-terminal peptides.

Authors:  Latisha D Heinlen; Lauren L Ritterhouse; Micah T McClain; Michael P Keith; Barbara R Neas; John B Harley; Judith A James
Journal:  J Mol Med (Berl)       Date:  2010-04-17       Impact factor: 4.599

Review 6.  Treatment of acute neuropsychiatric lupus with intravenous immunoglobulin (IVIG): a case report and review of the literature.

Authors:  Aaron M Milstone; Kevin Meyers; Josephine Elia
Journal:  Clin Rheumatol       Date:  2005-01-21       Impact factor: 2.980

7.  International multicenter evaluation of autoantibodies to ribosomal P proteins.

Authors:  Michael Mahler; Kai Kessenbrock; Magdalena Szmyrka; Yoshinari Takasaki; Ignacio Garcia-De La Torre; Yehuda Shoenfeld; Falk Hiepe; Chen Shun-le; Carlos A von Mühlen; Henning Locht; Peter Höpfl; Allan Wiik; Westley Reeves; Marvin J Fritzler
Journal:  Clin Vaccine Immunol       Date:  2006-01

8.  Relationship between clinical factors and neuropsychiatric manifestations in systemic lupus erythematosus.

Authors:  Yasuhiro Shimojima; Masayuki Matsuda; Takahisa Gono; Wataru Ishii; Shu-ichi Ikeda
Journal:  Clin Rheumatol       Date:  2005-03-02       Impact factor: 2.980

9.  Distribution of human leukocyte antigen alleles in systemic lupus erythematosus patients with angiotensin converting enzyme insertion/deletion polymorphism.

Authors:  Nageen Hussain; Ghazala Jaffery
Journal:  Bosn J Basic Med Sci       Date:  2013-02       Impact factor: 3.363

10.  Significance of antibodies against the native ribosomal P protein complex and recombinant P0, P1, and P2 proteins in the diagnosis of Chinese patients with systemic lupus erythematosus.

Authors:  Jing Li; Ying Shen; Jing He; Rulin Jia; Xiujie Wang; Xiaosan Chen; Dahai Wang; Lei Han; Lei Zhu; Xiaofeng Chi; Sandra Saschenbrecker; Cornelia Dähnrich; Winfried Stöcker; Wolfgang Schlumberger; Zhan-Guo Li
Journal:  J Clin Lab Anal       Date:  2013-02-11       Impact factor: 2.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.